Latest news for Skinvisible (OTC:SKVI) Stock

Skinvisible Inc is a pharmaceutical research and development company that has developed and patented a polymer delivery system, Invisicare and formulated over forty topical skin products, which it out-licenses globally. Invisicare is a patented polymer delivery system that enhances the delivery of active ingredients for topically applied skin care products. Its patented technology has a formula and process for combining active ingredients with a delivery system that extends the duration of time the product remains on the skin and active. The Company is also exploring new opportunities in large medical markets outside of the dermatology market such as obesity and other potential markets where a topical or transdermal solution would be a viable alternative.

Biotech

News

Penny Stocks

Health Care

Movers

Trading Ideas

General

QNRX

SKVI

Why Are Quoin Pharma Shares Trading Higher Today?

Movers & Shakers

Intraday Update

Markets

ABMD

ACRGF

ADMP

ADMS

ADTN

AERI

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

ARDS

ARGGY

ASASF

ASBFY

AUPH

AVCO

AVEW

AXAS

AXDDF

AXGN

AZRX

BCUCY

BEAT

BHKLY

BIEI

BKEAY

BLOZF

BLUU

BTHCF

BYDDY

CARG

CBAY

CDTI

CERS

CHKDP

CHYHY

CLLS

CMPNF

CMVLF

CNPOF

CNSL

CNTMF

CPPMF

CRSXF

CRUUF

CTAIF

CTEQF

CTRA

CTST

CTXR

CXXIF

DERM

DFILF

DMPI

DSFGY

DXBRF

DYMEF

EEGI

EEVVF

ENOB

ESTR

EUUNF

EXXAY

FFXXF

FIXX

FLDM

FLWPF

FRLI

FSSN

FUTL

GEMP

GLMD

GORAF

GYNAF

HABT

HCAT

HEXO

HITIF

HOTH

HSNGY

HTBX

ICPT

IPWR

IRNC

JASN

JCAP

JSHLY

KOPN

KPCPY

KWBT

LBRT

LEMIF

LYFT

MAKSY

Stocks That Hit 52-Week Lows On Thursday

Skinvisible Inc

Press Releases

Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome

Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal Treatment

Skinvisible Expands Obesity Patent Application for Transdermal Delivery

Skinvisible Unveils Promising Data on Transdermal Obesity Formulations

Promising Data on Transdermal Obesity Formulations Announced by Skinvisible

Skinvisible

<ul>
	<li>The&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/22/06/ac27562566/skinvisible-announces-first-invisicare-delivery-technology-product-to-receive-u-s-fda-acceptance-" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">FDA has accepted</a>&nbsp;Quoin Pharmaceuticals Inc&#39;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) Investigational New Drug (IND) application for its licensed formulation, which uses&nbsp;Skinvisible Inc&#39;s&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/SKVI#OTC">SKVI</a>) Invisicare drug delivery technology.&nbsp;</li>
	<li>The topical formulation &quot;QRX003&quot; was developed to treat Netherton&#39;s Syndrome, a debilitating hereditary disorder that affects the skin, hair, and the immune system.</li>
	<li>Skinvisible granted Quoin an exclusive, royalty-bearing license to its technology for use in select Orphan Rare Skin Diseases and the right to use its proprietary formula and technology to develop products that will target several rare skin-related indications.&nbsp;</li>
	<li>Related:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/news/22/04/26790957/why-quoin-pharmaceuticals-stock-is-trading-higher" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">Why Quoin Pharmaceuticals Stock Is Trading Higher</a>.</li>
	<li>Quoin is responsible for obtaining all FDA and other regulatory body approvals necessary to market the products in the U.S. and other countries.&nbsp;</li>
	<li>Upon completing various clinical and regulatory milestones, Skinvisible is entitled to receive a milestone payment of $5 million and ongoing royalties from sales.</li>
	<li>Price Action:&nbsp;QNRX shares are up 7.13% at $0.66 during the market session on the last check Monday.</li>
</ul>

Skinvisible, Inc. (&quot;Skinvisible&quot;) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/SKVI#OTCQB">SKVI</a>), is pleased to announce that its licensee Quoin Pharmaceuticals, Inc. (&quot;Quoin&quot;) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>), has received U.S. FDA acceptance of its Investigational New Drug (IND) application for its licensed formulation which uses Skinvisible&#39;s Invisicare&reg; proprietary drug delivery technology. The topical formulation &quot;QRX003&quot; was developed to treat Nethertons Syndrome, a debilitating hereditary disorder that affects the skin, hair and the immune system. There currently is no cure or approved treatment for Netherton Syndrome.

&quot;This is the first IND approval by the FDA which includes our Invisicare technology as the delivery platform, and it further reinforces our vision of developing topical therapeutics for a number of key indications. It is an important milestone for Skinvisible and could potentially lead to other indications receiving approval,&quot; said Terry Howlett, President and CEO, Skinvisible. &quot;With the IND approved, the clinical trial will be underway shortly. We look forward to assisting Quoin in their success and potential FDA approval as well as potentially bringing a treatment to patients suffering from Nethertons Syndrome.&quot;

Skinvisible granted Quoin an exclusive, royalty-bearing license to its technology for use in select Orphan Rare Skin Diseases and for the right to use its proprietary formula as well as its technology to develop products that will target a number of rare skin related indications. Quoin is responsible for obtaining all FDA and other regulatory body approvals necessary to market the products in the US and other countries. Upon the successful completion of various clinical and regulatory milestones, Skinvisible is entitled to receive a milestone payment of $5 million and ongoing royalties from sales.

Quoin Pharmaceuticals Receives U.S. FDA Acceptance Of Its Investigational New Drug Application For Its Licensed Formulation Which Uses Skinvisible's Invisicare Proprietary Drug Delivery Technology

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Skinvisible

News

Latest news for Skinvisible (OTC:SKVI) Stock

Monday, June 06, 2022

Tuesday, March 24, 2020

Thursday, October 10, 2019